๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Camurus AB (publ) (STO:CAMX)
Sweden flag Sweden ยท Delayed Price ยท Currency is SEK
739.50
-0.50 (-0.07%)
Nov 20, 2026, 5:29 PM CET

Camurus AB Earnings Call Transcripts

Fiscal Year 2026

Fiscal Year 2025

  • 2025 saw strong revenue and profit growth, driven by Brixadi royalties and Buvidal expansion, despite FX headwinds and a UK distribution change. Regulatory milestones included Oczyesa approval and launch, while R&D advanced with positive CAM2056 results. 2026 guidance anticipates continued double-digit growth and increased investment in U.S. operations.

  • Strong clinical data for CAM2056 and expanding partnerships highlight growth in cardiometabolic and opioid use disorder markets. Regulatory progress for Octase and robust commercial uptake in key regions support a positive outlook, despite recent financial guidance adjustments.

  • Q3 2025 saw strong profitability, 18% revenue growth year-on-year, and robust cash flow, but full-year revenue guidance was lowered due to U.S. and U.K. headwinds. Product launches and pipeline progress continued, with Oczyesa launched in Germany and Brixadi gaining U.S. market share.

  • Record Q2 revenues and profitability driven by Buvidal and Brixadi growth, EU approval of Oxyceisa, and a major licensing deal with Eli Lilly. Strong cash position and maintained guidance, with further growth expected in H2 as funding and access improve.

  • A major partnership with Eli Lilly validates the FluidCrystal platform, while Brixadi and Buvidal continue to expand globally despite temporary Medicaid headwinds. CAM2029 and CAM2056 advance in late-stage trials, supporting a confident outlook for 40%-50% revenue growth in 2024.

  • Q1 2025 saw record profitability, 43% revenue growth, and strong Buvidal expansion in Europe and Australia. Brixadi U.S. royalties surged 185% year-over-year despite a 13% market decline, and regulatory progress for CAM2029 in acromegaly continues in the EU and U.S.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021

Fiscal Year 2020

Fiscal Year 2019